News and Publications

News

Blog Image

February 11, 2026

Histofy and West Midlands SDE Sign Contract to Deliver AI-Ready Histology Data

Blog Image

September 6, 2025

Histofy and Leica Biosystems Announce Global Reseller Agreement for AI-Powered Pathology Solutions

Blog Image

Histofy Achieves ISO 27001 and ISO 13485 Certification

Publications

Medical Image Analysis

Mitosis detection, fast and slow: Robust and efficient detection of mitotic figures

Lancet Digital Health

Development and validation of artificial intelligence-based prescreening of large-bowel biopsies taken in the UK and Portugal: a retrospective cohort study

November 1, 2023

The Journal of Pathology

Unleashing the potential of AI for pathology: challenges and recommendations

Screening of normal endoscopic large bowel biopsies with interpretable graph learning: a retrospective study

Medical Image Analysis

One model is all you need: Multi-task learning enables simultaneous histology image segmentation and classification

January 1, 2023

Lancet Digital Health

Development and validation of a weakly supervised deep learning framework to predict the status of molecular pathways and key mutations in colorectal cancer from routine histology images: a retrospective study

December 1, 2021

Medical Image Analysis

Hover-Net: Simultaneous segmentation and classification of nuclei in multi-tissue histology images

December 1, 2019

Histofy develops AI solutions for pathology to advance both clinical care and drug development. From cancer diagnostics to toxicologic assessment, our technologies support pathologists and scientists in delivering faster, more accurate, and insight-driven decisions for improved patient care and safe drug development.

Company Number: 13732208
VAT Number: GB 472 7836 55